Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) by Ignacio I Wistuba, Andrew Futreal, Xuemei Wang, Arvind Dasari, Cathy Eng, Scott Kopetz, Edwin R Parra, Cara L Haymaker, Eduardo Vilar, Robert A Wolff, Kanwal Raghav, Michael J Overman, Younghee Lee, Benny Johnson, Luisa Maren Solis Soto, Jane V Thomas, Van K Morris, Bryan K Kee, Christine M Parseghian, Daniele Lorenzini, Caddie Laberiano-Fernandez, Anuj Verma, Wenhua Lang

Get full text